Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

365.74
Real-Time Quote
 -3.90 / -1.06%
Today’s Change
257.69
Today|||52-Week Range
376.88
+32.88%
Year-to-Date
3 Drugs Stocks Dragging The Industry Down
1:38pm / TheStreet.com
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Oct 16 / Zacks.com
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
10:24am / Zacks.com
Resistance Is Futile
Oct 16 / TheStreet.com
UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patien...
8:16am / Benzinga
Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key App...
Oct 16 / Benzinga
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors
Oct 18 / TheStreet.com
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Oct 15 / MotleyFool.com
Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy - Analyst Blog
Oct 17 / Zacks.com
Bristol-Myers Collaborates for Opdivo-Imbruvica Combo - Analyst Blog
Oct 14 / Zacks.com
TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011
Oct 17 / Benzinga
Celgene's Otezla Encourages in Plaque Psoriasis at EADV - Analyst Blog
Oct 13 / Zacks.com
Notable 52-Week Highs and Lows of the Day 10/17: (REGN) (UNH) (CMRX) High; (URBN) (RP...
Oct 17 / Investing Channel
Top Trade Ideas For The Week Of October 13, 2014: The Rest
Oct 12 / StockTwits
3 Stocks Reiterated As A Buy: UNH, BIDU, REGN
Oct 17 / TheStreet.com
Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo - Analyst Blog
Oct 08 / Zacks.com
Cramer: Regeneron's Head-to-Head Results 'Very Positive'
Oct 17 / TheStreet.com
Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog
Oct 08 / Zacks.com
Benzinga's Volume Movers
Oct 17 / Benzinga
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - ...
Oct 08 / Zacks.com
Regeneron Pharmaceuticals (REGN) Rising Before The Market Opens
Oct 17 / TheStreet.com
Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog
Oct 07 / Zacks.com
EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both B...
Oct 17 / Benzinga
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Oct 07 / MotleyFool.com
'Mad Money' Lightning Round: Stay the Course With Facebook
Oct 17 / TheStreet.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.